---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218142"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-05-12T11:05:16+00:00"
generated_at: "2026-05-12T11:13:46.039323+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026

## Summary
- Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.
- Net loss Q1 2026: $53.1M vs $30.4M Q1 2025, driven by higher R&D spend.
- GAAP R&D expenses $49.2M (Q1 2026) vs $30.6M (Q1 2025); non-GAAP R&D $42.7M.
- Top-line data from pivotal Phase 3 OPERA-01 (palazestrant monotherapy) expected fall 2026.
- Initial Phase 1 data for OP-3136 to be presented at ASCO 2026.

## SEC filing metadata
- accession: 0001193125-26-218142
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-05-12T11:05:16+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/0001193125-26-218142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/olma-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218142
- JSON: https://secwatch.observer/filing/0001193125-26-218142.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218142.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $53.1 million, as compared to $30.4 million for the quarter ended Marc.
  - Period: the quarter ended March 31, 2026
  - Net income: Net loss for the quarter ended March 31, 2026 was $53.1 million, as compared to $30.4 million for the quarter ended Marc
  - Result: reported results
  source text: On May 12, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/0001193125-26-218142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.